NCT06340711 - Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 25, 2024

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2028

Conditions

Esophageal AdenocarcinomaGastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma

Interventions

DRUG

OBP-301

2×10(12) viral particles per injection given intratumorally every 2 weeks for a total of 4 injections starting on Day 1 of the study

DRUG

Pembrolizumab

400 mg IV given every 6 weeks starting on day 4 of the study and given for up to 2 years

Trial Locations (1)

RECRUITING

Weill Cornell Medicine/NewYork-Presbyterian Hospital, New York